Cite
Prediction of patients with a tumor proportion score >50% who do not respond to first-line monotherapy with pembrolizumab
MLA
Mitsunori Morita, et al. Prediction of Patients with a Tumor Proportion Score >50% Who Do Not Respond to First-Line Monotherapy with Pembrolizumab. Oct. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....aba15e4169f3ddb30dab780d6caa9105&authtype=sso&custid=ns315887.
APA
Mitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, Akihiro Tamiya, Hidekazu Suzuki, Katsuya Hirano, Yasushi Fukuda, Toshihide Yokoyama, Ryota Kominami, Masaki Kanazu, Junji Uchida, Satoshi Hara, Shuji Yamashita, & Hiromi Tomioka. (2019). Prediction of patients with a tumor proportion score >50% who do not respond to first-line monotherapy with pembrolizumab.
Chicago
Mitsunori Morita, Motohiro Tamiya, Daichi Fujimoto, Akihiro Tamiya, Hidekazu Suzuki, Katsuya Hirano, Yasushi Fukuda, et al. 2019. “Prediction of Patients with a Tumor Proportion Score >50% Who Do Not Respond to First-Line Monotherapy with Pembrolizumab,” October. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....aba15e4169f3ddb30dab780d6caa9105&authtype=sso&custid=ns315887.